Current treatment strategies for cancer, especially advanced cancer, are limited and unsatisfactory. One of the most substantial advances in cancer therapy, in the last decades, was the discovery of a new layer of immunotherapy approach, immune checkpoint inhibitors (ICIs), which can specifically acti...
Immune checkpoint inhibitors (CPIs) are highly effective immunotherapeutics that have transformed treatment paradigms for several cancers1,2,3,4,5,6. They block inhibitory immune checkpoint molecules, such as CTLA4 and PD-1, restoring immune activation and bolstering anti-tumour immunity. Simultaneous ...
Immune checkpoint inhibitors (ICPIs) are new cancer drugs that target self-tolerance pathways exploited by tumors to escape immune destruction, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligand (PD-L1). ...
免疫相关不良反应(immune-related adverse events,irAEs)是指使用免疫检查点抑制剂(Immune Checkpoint Inhibitors, ICIs)进行肿瘤治疗时可能出现的一系列副作用。这些副作用可能涉及到身体的各个器官系统,包括皮肤、肠道、内分泌、肺部和肌肉骨...
免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs),又称免疫系统反制点抑制剂,作用于免疫检查点,用于增强免疫应答,或者是解除免疫抑制。 从以下4方面介绍免疫检查点抑制剂 一.免疫检查点抑制剂(ICIs) 免疫检查点分子(immune checkpoint)是免疫系统中起抑制作用的调节分子,其对于维持自身耐受、防止自身免疫反应、以及...
The efficacy of immunotherapy with immune-checkpoint inhibitors depends on the intricate cross talk across the cells in the TME. Thus, to disentangle the mechanisms underlying—and ultimately predicting—patient response, it is essential to adopt a holistic strategy to study patients' tumors.1,98 To...
Immune checkpoint inhibitors (ICI) represent a class of immuno-oncology drugs consisting of monoclonal antibodies occurring against inhibitory receptors or ligands within the immune system including CTLA-4, PD-1, and PD-L1. ICI has transformed oncology in the last decade leading to increased response...
免疫检查点抑制剂(Immune checkpoint inhibitors,ICIs)已经彻底改变肝细胞癌(hepatocellular carcinoma, HCC)的治疗范式。然而,许多HCC病人对ICIs治疗仍然存在豁免以及疗效低下等问题。对于消化道肿瘤,饮食疗法成为肿瘤热门的治疗策略之一。目前尚不清楚饮食调节联合ICIs的疗法是否可用于缓解HCC免疫治疗较差的现状。该研究旨在...
Howard (Jack) West, MD et al. Immune Checkpoint Inhibitors. JAMA Oncol. 2015;1(1):115. Julie R. Brahmer et al. Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer. Cancer Immunol Res August 2013 1; 85....
In addition, the development of robust biomarkers to assist prediction of response and clinical benefits of immune-checkpoint inhibitor therapy is essential to further advance the field as precision immuno-oncology The therapeutic activity of immune-checkpoint inhibitors is the result of a complex interpl...